Cargando…
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912854/ https://www.ncbi.nlm.nih.gov/pubmed/24600298 http://dx.doi.org/10.2147/AHMT.S29462 |